NXTCL Share Price Performance
SEK 1.01
-0.05 (-4.72%)
Price SEK 1.01
Share Pricen/a
NextCell Pharma AB Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
NXTCL Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
NextCell Pharma AB Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 27, 2026
- -0.33
- 16.97%
- -449.88%
- 0%
About NXTCL
- Founded
- 2014
- Employees
- 24
- CEO
- WebsiteView website
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank; and QVance, the first dedicated provider of quality services for developers of advanced therapies. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
